CLYBL and B-cell chronic lymphocytic leukemia: Acalabrutinib received a registration for the treatment of CLL [81] due to positive results of two phase III randomised trials: ASCEND (acalabrutinib vs. investigator ́s choice of idelalisib + rituximab or BR) in relapsed/refractory CLL [78], and ELEVATE-TN (acalabrutinib vs. obinutuzumab + acalabrutinib vs. G-CLB) in untreated elderly/comorbid patients [82].